LeMaitre Vascular, Inc. to Issue Quarterly Dividend of $0.20 (NASDAQ:LMAT)

LeMaitre Vascular, Inc. (NASDAQ:LMAT) announced a quarterly dividend on Tuesday, April 29th, Wall Street Journal reports. Investors of record on Thursday, May 15th will be given a dividend of 0.20 per share by the medical instruments supplier on Thursday, May 29th. This represents a $0.80 annualized dividend and a yield of 0.97%. The ex-dividend date is Thursday, May 15th.

LeMaitre Vascular has raised its dividend payment by an average of 13.3% per year over the last three years and has raised its dividend annually for the last 14 consecutive years. LeMaitre Vascular has a payout ratio of 33.6% indicating that its dividend is sufficiently covered by earnings. Analysts expect LeMaitre Vascular to earn $2.17 per share next year, which means the company should continue to be able to cover its $0.80 annual dividend with an expected future payout ratio of 36.9%.

LeMaitre Vascular Stock Performance

Shares of NASDAQ LMAT opened at $82.46 on Tuesday. The company has a 50 day simple moving average of $84.06 and a two-hundred day simple moving average of $93.11. LeMaitre Vascular has a fifty-two week low of $71.42 and a fifty-two week high of $109.58. The company has a market capitalization of $1.86 billion, a price-to-earnings ratio of 45.06, a P/E/G ratio of 2.22 and a beta of 0.86.

LeMaitre Vascular (NASDAQ:LMAT) last posted its quarterly earnings results on Thursday, May 1st. The medical instruments supplier reported $0.48 earnings per share for the quarter, missing the consensus estimate of $0.50 by ($0.02). The company had revenue of $59.87 million during the quarter, compared to analysts’ expectations of $57.61 million. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. The business’s quarterly revenue was up 12.0% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.44 EPS. On average, analysts forecast that LeMaitre Vascular will post 1.94 earnings per share for the current fiscal year.

Insider Activity at LeMaitre Vascular

In other LeMaitre Vascular news, insider Trent G. Kamke sold 2,009 shares of the business’s stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $82.12, for a total transaction of $164,979.08. Following the completion of the sale, the insider now directly owns 5,564 shares in the company, valued at approximately $456,915.68. The trade was a 26.53% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 10.79% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

LMAT has been the subject of several recent analyst reports. Oppenheimer lowered LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a research report on Friday, February 28th. Barrington Research cut shares of LeMaitre Vascular from an “outperform” rating to a “market perform” rating in a report on Friday, February 28th. Lake Street Capital increased their price target on shares of LeMaitre Vascular from $105.00 to $110.00 and gave the company a “buy” rating in a report on Friday, February 28th. Finally, Wells Fargo & Company initiated coverage on shares of LeMaitre Vascular in a research report on Thursday, February 13th. They set an “equal weight” rating and a $95.00 price target for the company. Five research analysts have rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $98.14.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.